Zacks Investment Research
22 Jan 2026, 16:30 UTC · 39w ago
BioNTech (BNTX) Soars 11.8%: Is Further Upside Left in the Stock?
Impact · against what's priced in
BioNTech's Fast Track designation for BNT113 is a positive catalyst that offsets expected quarterly revenue declines of 32.2%. The stock's recent 11.8% rally reflects the market's immediate pricing of this regulatory progress.
- BNTX+0.40
No priced-in read yet
- In context
The FDA granting Fast Track designation for BNT113 in treating HPV16+ head and neck squamous cell carcinoma accelerates the path to commercialization, outweighing a projected quarterly loss of $0.57 per share.
Read from the article alone
Search tags
